StephenDouglasSmithMD

Hematology • Seattle, WA

Associate Professor, Fred Hutchinson Cancer Center

Join to view full profile

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Smith's full profile

Already have an account?

Office
825 Eastlake Ave E # G3-200
Seattle, WA 98109
Phone+1 206-606-6832

Fax+1 206-606-6831

Summary

Dr. Stephen Smith is a hematologist in Seattle, WA and is affiliated with multiple hospitals in the area, including Seattle Cancer Care Alliance and UW Medicine/University of Washington Medical Center. He received his medical degree from University of Southern California School of Medicine and has been in practice 19 years. He is experienced in immunotherapy, lymphoma, stem cell transplantation, and car t-cell therapy.

Clinical Expertise

Immunotherapy, Lymphoma, Stem cell transplantation, CAR T-cell Therapy

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2005 - 2008
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2002 - 2005
Keck School of Medicine of the University of Southern CaliforniaClass of 2002

Certifications & Licensure

CA State Medical License 2003 - Present
OR State Medical License 2011 - Present
WA State Medical License 2013 - 2026
OH State Medical License 2005 - 2012
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Start of enrollment: 2023 Aug 07
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Start of enrollment: 2023 Jan 26
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma Start of enrollment: 2021 Aug 03
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors Start of enrollment: 2022 May 19
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.
Narendranath Epperla, Adam S Zayac, Daniel J Landsburg, Allison M Bock, Grzegorz S Nowakowski
Blood Advances. 2024-10-22
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Michael Wang, Tadeusz Robak, Kami J Maddocks, Tycel Phillips, Stephen D Smith
Blood Advances. 2024-09-10
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial.
Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens
Haematologica. 2024-09-05

Journal Articles

Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
Stephen D. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management
60th American Society of Hematology Annual Meeting - 11/30/2018

Authored Content

Mantle Cell Lymphoma at ASH 2022 – More Answers, and More QuestionsDecember 2022

Press Mentions

SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member
NCCN
B-Cell Malignancies, Panel Member